Litcius/Paper detail

A Phase II Open-Label Study of Bermekimab in Patients with Hidradenitis Suppurativa Shows Resolution of Inflammatory Lesions and Pain

Alice B. Gottlieb, Nicola E. Natsis, Francisco A. Kerdel, Seth Forman, Edgar R. Gonzalez, Gilberto Jimenez, Liliam Hernández, Jessica Kaffenberger, Giancarlo Guido, Kathryn Jean Lucas, Diego P. Montes, Michael H. Gold, Chad Babcock, John Simard

2020Journal of Investigative Dermatology88 citationsDOI

Topics & Concepts

Hidradenitis suppurativaMedicineAdverse effectInternal medicineTumor necrosis factor alphaGastroenterologySubcutaneous injectionSurgeryDiseaseHidradenitis Suppurativa and TreatmentsColorectal and Anal CarcinomasChemotherapy-related skin toxicity
A Phase II Open-Label Study of Bermekimab in Patients with Hidradenitis Suppurativa Shows Resolution of Inflammatory Lesions and Pain | Litcius